Monday, July 03, 2023
Baudax Bio is a pharmaceutical company focused on innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBs) and a proprietary chemical reversal agent specific to these NMBs. For more information, please visit www.baudaxbio.com.
Gregory Aurand, Senior Vice President, Equity Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Who is TeraImmune? The privately-held company is based in Germantown, Maryland and is focused on novel regulatory T cells (Tregs) therapies for autoimmune disease. TeraImmune has an approved FDA IND for their TI-168 autologous Factor VIII (FVIII) T-cell receptor Treg cell therapy to eliminate clotting factor FVIII inhibitors in Hemophilia A patients. The combined company anticipates moving this IND to a Phase 1/2a trial, and also expects to advance the development of TeraImmune’s innovative immune-cell therapies platform designed for conditions that suppress unwanted immune reactions.
Why the acquisition? TeraImmune is largely composed of former NIH researchers with scientific expertise who have developed a novel therapeutic platform, but have limited clinical development experience. Baudax Bio’s team has a proven ability in executing and progressing clinical trials. The combined company pipeline will now carry a promising therapy that is expected to move into clinicals (TI-168; FVIII inhibitors), as well as have an expected IND filing (BX3000; NMB reversal agent) that will also move into clinicals. The acquisition could also help resolve Baudax Bio’s Nasdaq deficiency issues by providing additional equity.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.